ImmunoCellular Therapeutics Price Prediction
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
Oversold Vs Overbought
47
Oversold | Overbought |
ImmunoCellular Therapeutics stock price prediction is an act of determining the future value of ImmunoCellular Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of ImmunoCellular Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of ImmunoCellular Therapeutics and does not consider all of the tangible or intangible factors available from ImmunoCellular Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with ImmunoCellular Therapeutics, which may create opportunities for some arbitrage if properly timed.
It is a matter of debate whether pink sheet price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of ImmunoCellular Therapeutics based on different types of headlines from major news networks to social media. The ImmunoCellular stock price prediction module provides an analysis of price elasticity to changes in media outlook on ImmunoCellular Therapeutics over a specific investment horizon. Using ImmunoCellular Therapeutics hype-based prediction, you can estimate the value of ImmunoCellular Therapeutics from the perspective of ImmunoCellular Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in ImmunoCellular Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in ImmunoCellular Therapeutics to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying ImmunoCellular because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
ImmunoCellular Therapeutics after-hype prediction price | USD 0.47 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
ImmunoCellular |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ImmunoCellular Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ImmunoCellular Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of ImmunoCellular Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in ImmunoCellular Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of ImmunoCellular Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
ImmunoCellular Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting ImmunoCellular Therapeutics' pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on ImmunoCellular Therapeutics' historical news coverage. ImmunoCellular Therapeutics' after-hype downside and upside margins for the prediction period are 0.47 and 0.47, respectively. We have considered ImmunoCellular Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
ImmunoCellular Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of ImmunoCellular Therapeutics is based on 3 months time horizon.
ImmunoCellular Therapeutics Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as ImmunoCellular Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ImmunoCellular Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with ImmunoCellular Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 0 Events / Month | 3 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.47 | 0.47 | 0.00 |
|
ImmunoCellular Therapeutics Hype Timeline
ImmunoCellular Therapeutics is currently traded for 0.47. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. ImmunoCellular is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on ImmunoCellular Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 0.47. About 95.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. ImmunoCellular Therapeutics recorded earning per share (EPS) of 28.91. The entity last dividend was issued on the 16th of September 2020. The firm had 1:10 split on the 16th of September 2020. Given the investment horizon of 90 days the next anticipated press release will be uncertain. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.ImmunoCellular Therapeutics Related Hype Analysis
Having access to credible news sources related to ImmunoCellular Therapeutics' direct competition is more important than ever and may enhance your ability to predict ImmunoCellular Therapeutics' future price movements. Getting to know how ImmunoCellular Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how ImmunoCellular Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| NWBO | Northwest Biotherapeutics | 0.00 | 0 per month | 0.00 | (0.06) | 7.02 | (3.85) | 26.54 | |
| CPRX | Catalyst Pharmaceuticals | 0.37 | 9 per month | 2.43 | 0.02 | 4.05 | (3.73) | 15.45 | |
| OCTHF | Oxford Cannabinoid Technologies | 0.00 | 0 per month | 0.00 | 0.05 | 0.00 | 0.00 | 40.96 | |
| PHGUF | Pharming Group NV | 0.00 | 0 per month | 0.00 | (0.14) | 0.00 | (3.42) | 20.16 | |
| KNBIF | Kane Biotech | 0.00 | 0 per month | 0.00 | 0.15 | 11.11 | (3.45) | 43.71 | |
| HESG | Health Sciences Gr | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MMIRF | MedMira | 0.00 | 0 per month | 0.00 | 0.09 | 0.00 | 0.00 | 210.60 | |
| LBPH | Longboard Pharmaceuticals | 0.43 | 9 per month | 0.00 | (0.08) | 6.00 | (7.35) | 18.54 | |
| LUMO | Lumos Pharma | (0.07) | 9 per month | 0.00 | (0.03) | 5.35 | (4.14) | 22.73 | |
| CLRB | Cellectar Biosciences | (0.07) | 8 per month | 0.00 | (0.05) | 9.34 | (6.53) | 21.31 | |
| BOLT | Bolt Biotherapeutics | 0.00 | 6 per month | 3.67 | 0.02 | 7.14 | (5.84) | 21.42 |
ImmunoCellular Therapeutics Additional Predictive Modules
Most predictive techniques to examine ImmunoCellular price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for ImmunoCellular using various technical indicators. When you analyze ImmunoCellular charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About ImmunoCellular Therapeutics Predictive Indicators
The successful prediction of ImmunoCellular Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as ImmunoCellular Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of ImmunoCellular Therapeutics based on analysis of ImmunoCellular Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to ImmunoCellular Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to ImmunoCellular Therapeutics's related companies. Story Coverage note for ImmunoCellular Therapeutics
The number of cover stories for ImmunoCellular Therapeutics depends on current market conditions and ImmunoCellular Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that ImmunoCellular Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about ImmunoCellular Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |